Cloperastine: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 21: | Line 21: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Cloperastine.png|Cloperastine | |||
File:Cloperastine_synthesis.svg|Cloperastine synthesis | |||
</gallery> | |||
Latest revision as of 01:47, 17 February 2025
Cloperastine (INN) or cloperastine fendizoate (USAN) is a cough suppressant and antihistamine that has been in clinical use for decades in Japan, Hong Kong, and Europe. It was first registered in Japan in 1957 by Yoshitomi Pharmaceuticals. The usual adult dose is 20 mg, taken four times a day.
Pharmacology[edit]
Cloperastine acts as a histamine H1 receptor antagonist, meaning it blocks the action of histamine at the H1 receptor, which is primarily responsible for inflammation and allergic reactions. It also has antitussive (cough-suppressing) effects, which are thought to be due to its action on the cough center in the medulla oblongata of the brain.
Side Effects[edit]
The most common side effects of cloperastine are drowsiness and dry mouth. Other side effects can include constipation, blurred vision, and difficulty urinating. These side effects are generally mild and go away on their own after a few days of treatment.
Interactions[edit]
Cloperastine can interact with other medications, including other antihistamines, sedatives, tranquilizers, prescription pain medications, seizure medications, muscle relaxants, and medications for depression, anxiety, or psychiatric disorders. Patients should inform their doctor about all medications they are taking before starting treatment with cloperastine.


